{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:17:51Z","timestamp":1790882271142,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-003"],"award-info":[{"award-number":["2021-I2M-1-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248022"],"award-info":[{"award-number":["L248022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.trsl.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:28:52Z","timestamp":1769128132000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Peripheral PD-1\u207a T cell signatures predict immunotherapy response and survival in hepatobiliary cancers"],"prefix":"10.1016","volume":"288","author":[{"given":"Mingjian","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.trsl.2026.01.004_bib0001","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2026.01.004_bib0002","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.trsl.2026.01.004_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000543994","article-title":"Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study","author":"Piao","year":"2025","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.trsl.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"10.1016\/j.trsl.2026.01.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114052","article-title":"Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications","volume":"147","author":"Piao","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trsl.2026.01.004_bib0007","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.3389\/fimmu.2019.02936","article-title":"Immune checkpoints in circulating and tumor-infiltrating CD4+ T cell subsets in colorectal cancer patients","volume":"10","author":"Toor","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.01.004_bib0008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fimmu.2020.00125","article-title":"Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer","volume":"11","author":"Ottonello","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.trsl.2026.01.004_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-020-02686-6","article-title":"A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors","volume":"70","author":"Ando","year":"2021","journal-title":"Cancer Immunol Immunother CII"},{"issue":"4","key":"10.1016\/j.trsl.2026.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D\u2019Alessio","year":"2022","journal-title":"Hepatol Balt Md"},{"issue":"9","key":"10.1016\/j.trsl.2026.01.004_bib0011","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","article-title":"Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy","volume":"41","author":"Escobar","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.trsl.2026.01.004_bib0012","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2026.01.004_bib0013","first-page":"10","article-title":"TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer","volume":"174","author":"Koh","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"60","key":"10.1016\/j.trsl.2026.01.004_bib0014","doi-asserted-by":"crossref","first-page":"101994","DOI":"10.18632\/oncotarget.22025","article-title":"Expression of PD-1\/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients","volume":"8","author":"Arrieta","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2026.01.004_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.558248","article-title":"Immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types","volume":"11","author":"Araujo B de Lima","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.01.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer","volume":"13","author":"Inomata","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.trsl.2026.01.004_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nm.2084","article-title":"Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth","volume":"16","author":"Houghton","year":"2010","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.trsl.2026.01.004_bib0018","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.trsl.2026.01.004_bib0019","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.trsl.2026.01.004_bib0020","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1002\/cti2.1406","article-title":"Early-like differentiation status of systemic PD-1+CD8+ T\u2009cells predicts PD-1 blockade outcome in non-small cell lung cancer","volume":"11","author":"Khanniche","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.trsl.2026.01.004_bib0021","first-page":"113","article-title":"Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer","volume":"143","author":"Kim","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"17","key":"10.1016\/j.trsl.2026.01.004_bib0022","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","article-title":"Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas","volume":"25","author":"Rapp","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15","key":"10.1016\/j.trsl.2026.01.004_bib0023","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"18","key":"10.1016\/j.trsl.2026.01.004_bib0024","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.trsl.2026.01.004_bib0025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.trsl.2026.01.004_bib0026","first-page":"6659","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.trsl.2026.01.004_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426064","article-title":"Peripheral PD-1+NK cells could predict the 28-day mortality in sepsis patients","volume":"15","author":"Tang","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.trsl.2026.01.004_bib0028","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00262-022-03337-8","article-title":"PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-na\u00efve CRC patients","volume":"72","author":"Al-Mterin","year":"2023","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"10.1016\/j.trsl.2026.01.004_bib0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00262-024-03869-1","article-title":"Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer","volume":"74","author":"Ladjevardi","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.trsl.2026.01.004_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2015.12.006","article-title":"PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors","volume":"93","author":"Meniawy","year":"2016","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.trsl.2026.01.004_bib0031","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/2326-6066.CIR-22-0996","article-title":"Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma","volume":"11","author":"Saliby","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.trsl.2026.01.004_bib0032","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"24","key":"10.1016\/j.trsl.2026.01.004_bib0033","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:26:36Z","timestamp":1773991596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"alternative-id":["S1931524426000162"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.01.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral PD-1\u207a T cell signatures predict immunotherapy response and survival in hepatobiliary cancers","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}